Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 14/20 | 0.46 |
| ▸ | NOS1 | P29475 | 12/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 9/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | SI | P14410 | 2/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.35 |
| ▸ | ATP4A | P20648 | 2/20 | 0.35 |
| ▸ | ATP4B | P51164 | 2/20 | 0.35 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.35 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.35 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9668659 | 0.90 | NOS1 (0.36) | NOS2NOS1CYP2C9NOS3KDM4E | |
| SCHEMBL5663053 | 0.87 | NOS2 (0.44) | NOS2NOS1CYP2C9NOS3AURKA | |
| SCHEMBL10617543 | 0.80 | NOS2 (0.42) | NOS2NOS1CYP2C9NOS3ATP4A | |
| SCHEMBL8679184 | 0.77 | NOS2 (0.71) | NOS2NOS1CYP2C9NOS3KDM4E | |
| SCHEMBL9526170 | 0.76 | ATP4A (0.47) | NOS2NOS1CYP2C9NOS3KDM4E | |
| SCHEMBL9687860 | 0.76 | ATP4A (0.42) | NOS2NOS1CYP2C9NOS3ATP4A | |
| SCHEMBL9673068 | 0.76 | NOS2 (0.42) | NOS2NOS1CYP2C9NOS3ATP4A | |
| SCHEMBL9687927 | 0.75 | ATP4A (0.41) | NOS2NOS1CYP2C9NOS3KDM4E | |
| SCHEMBL9686863 | 0.75 | ATP4A (0.41) | NOS2NOS1CYP2C9NOS3KDM4E | |
| SCHEMBL5662760 | 0.74 | NOS2 (0.41) | NOS2NOS1CYP2C9NOS3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | claimed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | claimed |
| JP-2793905-B2 | — | — | 1998-09-03 | — | — | JP | claimed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | claimed |
| EP-0449935-B1 | COMPOUND WITH GASTRIC ACID INHIBITORY EFFECT AND PROCESS FOR ITS PREPARATION | HAESSLE AB (SE) | 1994-08-31 | — | — | EP | claimed |
| EP-0449935-A1 | COMPOUND WITH GASTRIC ACID INHIBITORY EFFECT AND PROCESS FOR ITS PREPARATION. | HAESSLE AB (SE) | 1991-10-09 | — | — | EP | claimed |
| US-5025024-A | Gastrointestinal inflammatory diseases; antiulcer agents | AKTIEBOLAGET HASSLE (SE) | 1991-06-18 | — | — | US | claimed |
| WO-1990006924-A1 | COMPOUND WITH GASTRIC ACID INHIBITORY EFFECT AND PROCESS FOR ITS PREPARATION | Aktiebolaget Hässle (SE) | 1990-06-28 | — | — | WO | claimed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| US-5441968-A | Therapeutically active fluoro substituted benzimidazoles | AKTIEBOLAGET HASSLE (SE) | 1995-08-15 | — | — | US | disclosed |
| EP-0449935-B1 | COMPOUND WITH GASTRIC ACID INHIBITORY EFFECT AND PROCESS FOR ITS PREPARATION | HAESSLE AB (SE) | 1994-08-31 | — | — | EP | disclosed |
| US-5049674-A | Antiulcer | AKTIEBOLAGET HASSLE (SE) | 1991-09-17 | — | — | US | disclosed |
| WO-1991009028-A1 | THERAPEUTICALLY ACTIVE FLUORO SUBSTITUTED BENZIMIDAZOLES, PROCESSES FOR THEIR PREPARATION AS WELL AS THEIR USE | Aktiebolaget Hässle (SE) | 1991-06-27 | — | — | WO | disclosed |
| US-5025024-A | Gastrointestinal inflammatory diseases; antiulcer agents | AKTIEBOLAGET HASSLE (SE) | 1991-06-18 | — | — | US | disclosed |
| US-5025024-A | Gastrointestinal inflammatory diseases; antiulcer agents | AKTIEBOLAGET HASSLE (SE) | 1991-06-18 | — | — | US | disclosed |
| WO-1990006924-A1 | COMPOUND WITH GASTRIC ACID INHIBITORY EFFECT AND PROCESS FOR ITS PREPARATION | Aktiebolaget Hässle (SE) | 1990-06-28 | — | — | WO | disclosed |
| WO-1990006924-A1 | COMPOUND WITH GASTRIC ACID INHIBITORY EFFECT AND PROCESS FOR ITS PREPARATION | Aktiebolaget Hässle (SE) | 1990-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | NOS2 2004/4885NOS1 1323/4885CYP2C9 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.